Status:
UNKNOWN
Glucagon Modulation of Ghrelin Secretion
Lead Sponsor:
Charite University, Berlin, Germany
Conditions:
Healthy Subjects
Obesity
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
As a counterregulatory hormone for insulin, glucagon plays a critical role in maintaining glucose homeostasis in vivo. It is well known that intramuscular glucagon administration stimulates growth hor...
Eligibility Criteria
Inclusion
- Subjects \> 18 and \< 60 years old.
- Patients with diabetes type 1 should fulfill the following criteria:
- ICT Insulin therapy was necessary within the first 3 months after diagnosis;
- HbA1c-Wert \< 7%.
Exclusion
- Diabetes type 1 or 2 (for the healthy group).
- Biochemical evidence of impaired hepatic or renal function.
- History of cardiovascular disease.
- Uncontrolled hypertension.
- Current inflammatory, malignant or psychiatric disease.
- Pregnancy
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00929812
Start Date
June 1 2006
End Date
December 1 2009
Last Update
June 30 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charite Campus Benjamin Franklin
Berlin, Germany, 12200